Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: Biology and clinical implications

Annals of Hematology

Volumn 78, Issue 6, 1999, Pages 251-264

  Strout, M P ^a   Marcucci, G ^a   Caligiuri, M A ^a   Bloomfield, C D ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Core binding factor; MLL

Indexed keywords

PROTEIN SUBUNIT; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER REGRESSION; CHROMOSOME 11Q; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 8; GENE DISRUPTION; GENE DUPLICATION; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; CORE BINDING FACTORS; DNA-BINDING PROTEINS; GENE REARRANGEMENT; HUMANS; LEUKEMIA, MYELOID; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; PROTO-ONCOGENES; TRANSCRIPTION FACTORS;

EID: 0033022964     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050511     Document Type: Review

References (123)

1. Mrózek K, Bloomfield CD (1998) Chromosome aberrations in de novo acute myeloid leukemia in adults: clinical implications. Rev Clin Exp Hematol 5:44-67
2. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A (1984) Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 11:332-350
3. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372:143-149
4. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064
5. Mrózek K, Heinonen K, de la Chapelle A, Bloomfield CD (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24:17-31
6. Ito Y (1996) Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia. J Cancer Res Clin Oncol 122:266-274
7. Tenen DG, Hromas R, Licht JD, Zhang DE (1997) Transcription factors, normal myeloid development, and leukemia. Blood 90:489-519
8. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M (1998) Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17:2994-3004
9. van der Reijden BA, Bloomfield CD, Touw IP, Jansen JH (1997) Acute leukemias with structurally altered core binding factor subunits. Leukemia 11:2217-2219
10. Sakakura C, Yamaguchi-Iwai Y, Satake M, Bae S, Takahashi A, Ogawa E, Hagiwara A, Takahashi T, Murakami A, Makino K (1994) Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/ MTGS(ETO) specific antisense oligonucleotide. Proc Natl Acad Sci USA 91:11723-11727
11. Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS (1998) Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol 60:217-225
12. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM (1998) ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/ mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95:10860-10865
13. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330
14. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marin-Padilla M, Tenen DG, Speck NA, Zhang DE (1997) Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303-306
15. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, Harada H, Downing JR (1998) Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91:3134-3143
16. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS (1993) Fusion between transcription factor CBFβ/PEBP2b and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044
17. van der Reijden BA, Dauwerse JG, Wessels JW, Beverstock GC, Hagemeijer A, van Ommen GJ, Breuning MH (1993) A gene for a myosin peptide is disrupted by the inv(16)(p13q22) in acute nonlymphocytic leukemia M4Eo. Blood 82:2948-2952
18. Claxton DF, Liu PP, Hsu HB, Marlton P, Hester J, Collins F, Deisseroth AB, Rowley JD, Siciliano MJ (1994) Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83:1750-1756
19. Hebert J, Cayuela JM, Daniel MT, Berger R, Sigaux F (1994) Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood 84:2291-2296
20. Adya N, Stacy T, Speck NA, Liu PP (1998) The leukemic protein core binding factor beta (CBFβeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol 18:7432-7443
21. Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M, Marin-Padilla M, Collins FS, Wynshaw-Boris A, Liu PP (1996) Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFβ-MYH11. Cell 87:687-696
22. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X, Bushweller JH, Bories JC, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA (1996) The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell 87:697-708
23. Castilla L, Liu P (1997) Analysis of a conditional CBFβ-MYH11 knock-in for inv(16) acute myeloid leukemia. Blood 90 [Suppl 1]: 58a
24. Castilla LH, Bodine DM, Garrett L, Liu PP (1998) Leukemia development by the induction of a second "hit" in chimeric mice containing CBFβ/MYH11 ES cells. Blood 92 [Suppl 1]: 214a
25. Nucifora G, Birn DJ, Erickson P, Gao J, LeBeau MM, Drabkin HA, Rowley JD (1993) Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 81:883-888
26. Liu PP, Hajra A, Wijmenga C, Collins FS (1995) Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 85:2289-2302
27. Langabeer SE, Walker H, Gale RE, Wheatley K, Burnett AK, Goldstone AH, Linch DC (1997) Frequency of CBFβl MYH11 fusion transcripts in patients entered into the UK MRC AML trials. Br J Haematol 96:736-739
28. Langabeer SE, Walker H, Rogers JR, Burnett AK, Wheatley K, Swirsky D, Goldstone AH, Linch DC (1997) Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol 99:925-928
29. Mrózek K, Prior T, Edwards C, Snyder PJ, Carroll AJ, Koduru PRK, Pettenati MJ, Archer KJ, Caligiuri MA, Kolitz J, Larson RA, Bloomfield CD (1998) A comparison of cytogenetic and molecular genetic detection of (8;21)(q22;q22) and inv(16)(p13q22) in adult de novo acute myeloid leukemia (AML): a Cancer and Leukemia Group B study. Blood 92 [Suppl 1]: 77a
30. Heim S, Mitelman F (1995) Cancer cytogenetics. Wiley-Liss, New York
31. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, Stoppa A, Marit G, Molina L, Michallet M (1995) Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 9:1491-1498
32. Schoch C, Haase D, Haferlach T, Gudat H, Buchner T, Freund M, Link H, Lengfelder E, Wandt H, Sauerland MC, Loffler H, Fonatsch C (1996) Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 10:1288-1295
33. Haferlach T, Bennett JM, Loffler H, Gassmann W, Andersen JW, Tuzuner N, Casslleth PA, Fonatsch C, Schoch C, Schlegelberger B, Becher R, Thiel E, Ludwig WD, Sauerland MC, Heinecke A, Buchner T (1996) Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. Leuk Lymphoma 23:227-234
34. Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD (1997) Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 15:466-475
35. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643-1650
36. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD (1983) Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: a unique cytogenetic-clinicopathological association. N Engl J Med 309:630-636
37. Grois N, Nowotny H, Tyl E, Krieger O, Kier P, Haas OA (1989) Is trisomy 22 in acute myeloid leukemia a primary abnormality or only a secondary change associated with inversion 16? Cancer Genet Cytogenet 43:119-129
38. Tosi P, Visani G, Ottaviani E, Testoni N, Bonifazi F, Pellacani A, Tura S (1998) Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. Eur J Haematol 60:161-165
39. Skipper HE, Schaebel FM, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-11
40. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP (1989) High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 7:1260-1267
41. Bloomfield CD, Herzig GP, Peterson BA, Wolff SN (1997) Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy. Cancer 80:2186-2190
42. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903
43. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ (1998) Frequency of prolonged remission duration following high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-1479
44. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J (1997) Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 80:2191-2198
45. Byrd JC, Dodge R, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD (1998) Adult acute myeloid leukemia (AML) patients (pts) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (Hi-DAC) are administered. Blood 92 [Suppl 1]: 312a
46. Gale PR, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, Dickie KA, Klein JP, Lowenberg B, Reiffers J, Rimm A, Rowlings P, Sandberg A, Sobocinski K, VeumStone J, Bortin M (1995) Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 16:203-208
47. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Biaise D, Reiffers J, Visani G, Sanz MA, Boogaerts MA, Lowenberg B, Gorin NC (1997) Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission. A European Group for Blood and Marrow Transplantation study. Blood 90:2921-2938
48. Grimwade D, Walker H, Oliver F, Wheatly K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 92:2322-2333
49. Burnett AK, Wheatley K, Langabeer S, Walker H, Linch D, Goldstone AH, Hann I, Stevens RF (1997) Outcome of acute myeloid leukemias affecting core binding factor subunits: the UK MRC experience. Blood 90 [Suppl 1]: 390a
50. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P (1995) Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85:2632-2638
51. Lo Coco F, Diverio D, Avvisati G, Luciano A, De Santis S, Santoro A, Pane F, Martinelli G, Pelicci PG, Vegna ML, Saglio G, Biondi A, Mandelli F (1997) Prospective RT-PCR monitoring of minimal residual disease in acute promyelocytic leukemia (APL) patients enrolled in the multicentric GINEMA-AIEOP "AIDA" trial. Blood 90 [Suppl 1]: 390a
52. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735-739
53. Saunders MJ, Tobal K, Yin JA (1994) Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leukemia Res 18:891-895
54. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD (1996) Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 88:2183-2191
55. Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N, Okamoto S, Kizaki M, Ikeda Y (1996) Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 95:85-94
56. Tobal K, Yin JA (1996) Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 88:3704-3709
57. Marcucci G, Caligiuri MA, Bloomfield CD (1997) Defining the "absence" of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 90:5022-5024
58. Costello R, Sainty D, Biaise D, Gastaut JA, Gabert J, Poirel H, Buzyn-Veil A, Macintyre E (1997) Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia. Blood 89:2222-2223
59. Evans PA, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR, Davies F, Tobal K, Liu Yin JA, Morgan GJ (1997) Detection and quantitation of the CBFβeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 11:364-369
60. Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A, Scholten C, Thalhammer-Scherrer R, Brugger S, Keil F, Schwarzinger I, Haas OA, Lechner K, Jaeger U (1998) Competitive CBFβeta/MYH11 reverse-transcription polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 16:1519-1525
61. Marcucci G, Livak KJ, Bi WL, Strout MP, Bloomfield CD, Caligiuri MA (1998) Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12:1482-1489
62. Bernard OA, Berger R (1995) Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer 13:75-85
63. Pui CH, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH, Evans WE, Crist WM, Krance RA (1995) Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 9:1990-1996
64. Smith MA, McCaffrey RP, Karp JE (1996) The secondary leukemias: challenges and research directions. J Natl Cancer Inst 88:407-408
65. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg AA, Chaganti RSK, Larson RA, LeBeau MM, Diaz MO, Rowley JD (1993) Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 329:909-914
66. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrózek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Nagesh Rao P, Herzig GP, Powell B, Ruutu T, Schiffer CA, Bloomfield CD (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59
67. Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KR, Strout MP, Hutchinson RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD (1997) Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23:A Cancer and Leukemia Group B study. Blood 90:4532-4538
68. Caligiuri MA, Schichman SA, Strout MP, Mrózek K, Baer MR, Frankel SR, Barcos M, Herzig GP, Croce CM, Bloomfield CD (1994) Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res 54:370-373
69. Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F, Moorman AV, Secker-Walker LM (1998) Ten novel 11q23 chromosomal partner sites. Leukemia 12:811-822
70. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R III, Patel Y, Harden A, Rubinelli P, Smith SD, LeBeau MM, Rowley JD, Diaz MO (1991) Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 88:10735-10739
71. Cimino G, Rapanotti MC, Elia L, Biondi A, Fizzotti M, Testi AM, Tosti S, Croce CM, Canaani E, Mandelli F, et al (1995) ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res 55:1625-1628
72. Tkachuk DC, Kohler S, Cleary ML (1992) Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71:691-700
73. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA (1992) A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 2:13-118
74. Nilson I, Lochner K, Siegler G, Greil J, Beck JD, Fey GH, Marschalek R (1996) Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias. Br J Haematol 93:966-972
75. Rasio D, Schichman SA, Negrini M, Canaani E, Croce CM (1996) Complete exon structure of the ALL1 gene. Cancer Res 56:1766-1769
76. Ennas MG, Sorio C, Greim R, Nieddu M, Scarpa A, Orlandini S, Croce CM, Fey GM, Marschalek R (1997) The ALL1/MLL/HRX antigen is predominantly localized in the nucleus of resting and proliferating peripheral blood mononuclear cells. Cancer Res 57:2035-2041
77. Butler LH, Slany R, Cui X, Cleary ML, Mason DY (1997) The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures. Blood 89:3361-3370
78. Rogaia D, Grignani F, Carbone R, Riganelli D, LoCoco F, Nakamura F, Croce CM, Di Fiore PP, Pelicci PG (1997) The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner. Cancer Res 57:799-802
79. Cross SH, Meehan RR, Nan X, Bird A (1997) A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 16:256-259
80. Reeves R, Nissen MS (1990) The AT-hook DNA binding domain of mammalian high mobility group chromosomal proteins: a novel peptide motif for recognizing DNA structure. J Biol Chem 265:8573-8582
81. Aravind L, Landsman D (1998) AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res 26:4413-4421
82. Cui X, De Vivo I, Slany R, Miyamoto A, Firestein R, Cleary ML (1998) Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet 18:331-337
83. De Vivo I, Cui X, Domen J, Cleary ML (1998) Growth stimulation of primary B cell precursors by the anti-phosphatase Sbfl. Proc Natl Acad Sci U S A 95:9471-9476
84. Zeleznik-Le NJ, Harden AM, Rowley JD (1994) 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci U S A 91:10610-10614
85. Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, Leshkowitz D, Croce CM, Canaani E (1995) Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia. Proc Natl Acad Sci USA 92:12160-12164
86. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ (1995) Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378:505-508
87. Hess JL, Yu BD, Li B, Hanson R, Korsmeyer SJ (1997) Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 90:1799-1806
88. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ (1998) MLL, a mammalian trithorax-group, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci USA 95:10632-10638
89. Roszenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E (1998) The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci U S A 95:4152-4157
90. Simon J (1995) Locking in stable states of gene expression: transcriptional control during Drosophila development. Curr Opin Cell Biol 7:376-385
91. Fidanza V, Melotti P, Yano T, Nakamura T, Bradley A, Canaani E, Calabretta B, Croce CM (1996) Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res 56:1179-1183
92. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E (1997) Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876-4885
93. Repp R, Borkhardt A, Haupt E, Kreuder J, Brettreich S, Hammermann J, Nishida K, Harbott J, Lampert F (1995) Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis. Leukemia 9:210-5
94. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P (1998) Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 92:574-588
95. Secker-Walker LM (1998) General report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997. Leukemia 12:776-778
96. Johansson B, Moorman AV, Seeker-Walker LM (1998) Derivative chromosomes of 11q23-translocations in hematologic malignancies. Leukemia 12:828-833
97. Gill Super H, Strissel PL, Sobulo OM, Burian D, Reshmi SC, Roe B, Zeleznik-Le NJ, Diaz MO, Rowley JD (1997) Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia. Genes Chromosomes Cancer 20:185-195
98. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, Rabbitts TH (1996) An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85:853-861
99. Lavau C, Szilvassy SJ, Slany R, Cleary ML (1997) Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 16:426-437
100. Cherif D, Bernard O, Paulien S, James MR, Le Paslier D, Berger R (1994) Hunting 11q23 deletions with fluorescence in situ hybridization (FISH). Leukemia 8:578-586
101. Harbott J, Mancini M, Verellen-Dumoulin C, Moorman AV, Seeker-Walker LM (1998) Hematological malignancies with a deletion of 11q23:cytogenetic and clinical aspects. Leukemia 12:823-827
102. Bower M, Parry P, Carter M, Lillington DM, Amess J, Lister TA, Evans G, Young BD (1994) Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood 84:3776-30
103. Slovak ML, Traweek ST, Willman CL, Head DR, Kopecky KJ, Magenis RE, Appelbaum FR, Forman SJ (1995) Trisomy 11: an association with stem/progenitor cell immunophenotype. Br J Haematol 90:266-273
104. Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, Debert C, Leboeuf D, Bastard C, Picard F, Veil-Buzyn A, Flandrin G, Bernard O, Macintyre E (1996) Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 87:2496-2505
105. Schichman SA, Caligiuri MA, Gu Y, Strout MP, Canaani E, Bloomfield CD, Croce CM (1994) ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci USA 91:6236-6239
106. Schichman SA, Caligiuri MA, Strout MP, Carter SL, Gu Y, Canaani E, Bloomfield CD, Croce CM (1994) ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res 54:4277-4280
107. Caligiuri MA, Strout MP, Oberkircher AR, Yu F, de la Chapelle A, Bloomfield CD (1997) The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. Proc Natl Acad Sci USA 94:3899-3902
108. So CW, Ma ZG, Price CM, Dong S, Chen SJ, Gu LJ, So CKC, Wiedemann LM, Chan LC (1997) MLL self-fusion mediated by Alu repeat homologous recombination and prognosis of AML-M5/M5 subtypes. Cancer Res 57:117-122
109. Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA (1998) The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci USA 95:2390-2395
110. Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP, Baer MR, Schiffer CA, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Schulman P, Pedersen-Bjergaard J, Croce CM, Bloomfield CD (1996) Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56:1418-1425
111. Bernard OA, Romana SP, Schichman SA, Mauchauffe M, Jonveaux P, Berger R (1995) Partial duplication of HRX in acute leukemia with trisomy 11. Leukemia 9:1487-1490
112. Marcucci G, Strout MP, Bloomfield CD, Caligiuri MA (1998) Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res 58:790-793
113. Caldas C, So CW, MacGregor A, Ford AM, MacDonald B, Chan LC, Wiedemann LM (1998) Exon scrambling of MLL transcripts occurs commonly and mimics partial genomic duplication of the gene. Gene 208:167-176
114. Schnittger S, Wormann B, Hiddemann W, Griesinger F (1998) Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood 92:1728-1734
115. Uckun FM, Herman-Hatten K, Crotty ML, Sensel MG, Sather HN, Tuel-Ahlgren L, Sarquis MB, Bostrom B, Nachman JB, Steinherz PG, Gaynon PS, Heerema N (1998) Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 92:810-814
116. Dolken G, Illerhaus G, Hirt C, Mertelsmann R (1996) BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 14:1333-1344
117. Biernaux C, Loos M, Sells A, Huez G, Stryckmans P (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86:3118-3122
118. Muller JR, Janz S, Goedert JJ, Potter M, Rabkin CS (1995) Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci USA 92:6577-6581
119. Kwong YL (1997) Partial duplication of the MLL gene in acute myelogenous leukemia without karyotypic aberration. Cancer Genet Cytogenet 97:20-24
120. Pui CH, Kane JR, Crist WM (1995) Biology and treatment of infant leukemias. Leukemia 9:762-769
121. Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrozek K, Strout MP, Davey FR, Schiffer CA, Bloomfield CD (1998) Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 12:317-325
122. Martinez-Climent JA, Espinosa Rr, Thirman MJ, Le Beau MM, Rowley JD (1995) Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. Identification of the t(9;11) as an indicator of long survival. J Ped Hematol Oncol 17:277-283
123. Heinonen K, Mrózek K, Lawrence D, Arthur DC, Pettenati MJ, Stamberg J, Qumsiyeh MB, Verma RS, MacCallum J, Schiffer CA, Bloomfield CD (1998) Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol 101:513-520